Experimental diabetes drugs offer patients hope

June 11, 2012 by LINDA A. JOHNSON

Some experimental diabetes treatments in late testing offer patients hope of better controlling their blood sugar and weight and preventing dangerously low blood sugar, all big challenges for millions of diabetics.

Results from studies of several new diabetes medicines and insulin products, just announced at the premiere U.S. conference for diabetes specialists, likewise hold the promise of billions in annual revenue for drugmakers that have dominated the diabetes market and for others breaking into it. They have been presenting their data at the conference, held in Philadelphia from last Friday through Monday.

Until the last decade, relatively few companies made treatments for diabetes, a in which the body either does not make enough insulin to break down the sugar in foods or uses insulin inefficiently.

Now many more drugmakers have jumped in, as the number of American is about 26 million and growing fast, and there are tens of millions more in , China and India.

That's because the global has caused a similar explosion of diabetes cases. About 95 percent are Type 2 diabetes, usually related to being overweight and sedentary. Type 2, once called adult-onset diabetes, now is also being diagnosed in adolescents, just like insulin-dependent , which used to be called juvenile diabetes.

Both types can cause early death or devastating complications — blindness, amputations, stroke, kidney disease, heart disease and more — when too-high blood sugar steadily damages organs and blood vessels.

Roughly $200 billion a year is spent on treating diabetes and indirect costs such as missed work and premature death, according to the diabetes association.

Last year, U.S. spending on diabetes medicines among insured patients for the first time exceeded spending on cholesterol drugs, according to Express Scripts, a top prescription benefit manager.

"We expect the key diabetes brands and markets to exhibit sustainable high-single-digit growth," reaching about $54 billion a year by 2020, Jefferies & Company analyst Jeffrey Holford recently wrote to investors. He cited an aging Western population, more health care use and adoption of Western diets in emerging countries, and increased use of new treatments and combination therapies.

Holford expects Denmark's Novo Nordisk AS to remain the top diabetes company by revenue but Eli Lilly and Co. of Indianapolis to overtake France's Sanofi SA as the No. 2 player by 2017.

Among other research, the conference highlighted promising new treatments likely to be approved in the next few years:

—Novo Nordisk on Friday reported on results of degludec, its ultra-long-acting insulin for patients with Type 2 diabetes. Its yearlong, 1,030-patient study compared degludec with Sanofi's Lantus, the world's top-selling insulin. Degludec reduced during the night, when it's most dangerous, by 36 percent and also reduced severe hypoglycemia significantly, compared to Lantus. Those problems occurred less than once in a year in both groups of patients, though.

Novo also reported on other studies finding that because degludec is active in the body for more than the standard 24 hours for long-acting insulins, patients can maintain good blood sugar control even if they don't take it at the same time every day. The Food and Drug Administration was to decide whether to approve U.S. sales by June 29, but just pushed that back until Oct. 29 to allow more time to review data.

—Johnson & Johnson's Janssen Research unit presented five late-stage studies on its daily pill, canagliflozin, part of a newer class of diabetes drugs called SGLT2 inhibitors. They work primarily by increasing how much glucose is excreted in urine. One yearlong study found it reduced long-term blood sugar levels, called A1C levels, and also helped patients lose much more weight than Merck & Co.'s blockbuster pill Januvia. Januvia is in a class called DPP-4 inhibitors, which increase the body's release of insulin after a meal.

Another study similarly showed canagliflozin decreased A1C levels and body weight significantly more than Sanofi's pill Amaryl. J&J applied for U.S. approval of its drug on May 29.

—On Sunday afternoon, Eli Lilly and partner Boehringer Ingelheim of Germany released results from two mid-stage studies of their new short-acting insulin, known as LY2605541. In separate studies comparing it to Lantus, it was slightly better at reducing blood sugar levels in Type 1 diabetics and about the same in Type 2 diabetics. In the eight-week Type 1 study, patients getting LY2605541 lost about 2.5 pounds (1.13 kilograms) on average while those on Lantus gained 1.5 pounds (0.68 kilograms). Weight changes were similar, but smaller, in the Type 2 study.

LY2605541 still must go through late-stage testing before approval can be sought.

—Other companies were presenting data on an experimental patch to deliver insulin pain-free and two devices in early development that would work like an artificial pancreas, monitoring continuously to help control when an insulin pump releases the hormone into the patient's blood.

Explore further: Which diabetes drug is best for diabetics with kidney disease?

shares

Related Stories

Which diabetes drug is best for diabetics with kidney disease?

November 13, 2011
Some blood-sugar-lowering drugs have caused kidney problems in patients with type 2 diabetes, so physicians are especially cautious when prescribing these agents to diabetics who also have chronic kidney disease (CKD).

FDA approves first diabetes-cholesterol combo pill

October 7, 2011
(AP) -- The first combination pill for the millions of people with the dangerous combination of diabetes and high cholesterol won U.S. approval Friday, offering convenience - and savings - to patients taking multiple pills.

FDA questions safety of experimental diabetes drug

July 15, 2011
(AP) -- Federal health regulators have concerns about bladder and breast cancer seen in patients taking an experimental diabetes pill from Bristol-Myers Squibb and AstraZeneca.

Recommended for you

Screen time linked to diabetes

July 28, 2017
Daily screen time of three or more hours is linked to several risk factors associated with the development of diabetes in children, according to a study by St George's, University of London.

People who drink 3 to 4 times per week less likely to develop diabetes than those who never drink: study

July 27, 2017
Frequent alcohol consumption is associated with a reduced risk of diabetes in both men and women, according to a new study published in Diabetologia (the journal of the European Association for the Study of Diabetes), with ...

Diabetes can be tracked with our Google searches

July 26, 2017
The emergence of Type 2 Diabetes could be more effectively monitored using our Google searches—helping public health officials keep track of the disease and halt its spread—according to research by the University of Warwick.

Scientists discover a new way to treat type 2 diabetes

July 21, 2017
Medication currently being used to treat obesity is also proving to have significant health benefits for patients with type 2 diabetes. A new study published today in Molecular Metabolism explains how this therapeutic benefit ...

Alzheimer's drug cuts hallmark inflammation related to metabolic syndrome by 25 percent

July 20, 2017
An existing Alzheimer's medication slashes inflammation and insulin resistance in patients with metabolic syndrome, a potential therapeutic intervention for a highly dangerous condition affecting 30 percent of adults in the ...

Diabetes or its precursor affects 100 million Americans

July 19, 2017
Almost one-third of the US population—100 million people—either has diabetes or its precursor condition, known as pre-diabetes, said a government report Tuesday.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.